Patients with HER2-mutant NSCLC have a high incidence of BM, with point estimates between 9–32% of patients, making these patients more likely to develop BM than KRAS or EGFR-mutant NSCLC [66,67,68,69,70,71,74,75]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.